MEDPACE HOLDINGS INC (MEDP) Forecast, Price Target & Analyst Ratings
NASDAQ:MEDP • US58506Q1094
470.59 USD
+1.21 (+0.26%)
At close: Mar 6, 2026
471 USD
+0.41 (+0.09%)
After Hours: 3/6/2026, 6:33:29 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDPACE HOLDINGS INC (MEDP).
Forecast Snapshot
Consensus Price Target
$497.46
+ 5.71% Upside
Next Earnings Forecast
Release DateApr 20, 2026
PeriodQ1 / 2026
EPS Estimate$3.98
Revenue Estimate712.08M
ChartMill Buy Consensus
52.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$497.46
Upside
+ 5.71%
From current price of $470.59 to mean target of $497.46, Based on 18 analyst forecasts
Low
$341.82
Median
$502.35
High
$611.10
Price Target Revisions
1 Month
-10.20%
3 Months
-9.01%
Price Target Summary
18 analysts have analysed MEDP and the average price target is 497.46 USD. This implies a price increase of 5.71% is expected in the next year compared to the current price of 470.59.
The average price target has been revised downward by 9.01% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
52.22%
MEDP was analyzed by 18 analysts. The buy percentage consensus is at 52. So analysts seem to be rather neutral about MEDP.
In the previous month the buy percentage consensus was at a similar level.
MEDP was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2026-03-03 | RBC Capital | Initiate | Outperform |
| 2026-02-18 | TD Cowen | Upgrade | Sell -> Hold |
| 2026-02-13 | Jefferies | Upgrade | Hold -> Buy |
| 2026-02-11 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2026-02-11 | Barclays | Maintains | Underweight -> Underweight |
| 2026-02-11 | Truist Securities | Maintains | Hold -> Hold |
| 2025-12-15 | Barclays | Maintains | Underweight -> Underweight |
| 2025-11-13 | BMO Capital | Initiate | Market Perform |
| 2025-10-24 | TD Cowen | Maintains | Sell -> Sell |
| 2025-10-24 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-24 | Barclays | Maintains | Underweight -> Underweight |
| 2025-10-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Downgrade | Equal-Weight -> Underweight |
| 2025-09-09 | Jefferies | Maintains | Hold -> Hold |
| 2025-09-03 | Rothschild & Co | Downgrade | Buy -> Neutral |
| 2025-07-29 | UBS | Downgrade | Neutral -> Sell |
| 2025-07-25 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-07-23 | TD Cowen | Downgrade | Hold -> Sell |
| 2025-07-23 | Deutsche Bank | Maintains | Hold -> Hold |
| 2025-07-23 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-23 | Truist Securities | Maintains | Hold -> Hold |
| 2025-07-23 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-24 | Barclays | Initiate | Equal-Weight |
| 2025-04-23 | Truist Securities | Maintains | Hold -> Hold |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 20, 2026
PeriodQ1 / 2026
EPS Estimate$3.98
Revenue Estimate712.08M
Revenue Q2Q27.48%
EPS Q2Q8.37%
Number of Analysts13
Next Earnings Revisions
Revenue (1 Month)
2.42%
Revenue (3 Months)
2.43%
EPS (1 Month)
1.41%
EPS (3 Months)
2.05%
Next Earnings Summary
MEDP is expected to report earnings on 4/20/2026. The consensus EPS estimate for the next earnings is 3.98 USD and the consensus revenue estimate is 712.08M USD.
The next earnings revenue estimate has been revised upward by 2.43% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.886B 29.17% | 2.109B 11.84% | 2.53B 19.97% | 2.861B 13.07% | 3.074B 7.44% | 3.362B 9.37% | 3.84B 14.22% | 4.214B 9.74% | 4.643B 10.18% | 5.111B 10.08% | 5.135B 0.47% | |
| EBITDA YoY % growth | 363.153M 20.61% | 476.121M 31.11% | 563.059M 18.26% | 629.58M 11.81% | 690.67M 9.70% | 767.26M 11.09% | 871.9M 13.64% | 973.86M 11.69% | 1.084B 11.31% | 1.206B 11.25% | 1.256B 4.15% | |
| EBIT YoY % growth | 336.825M 20.86% | 446.87M 32.67% | 534.935M 19.71% | 601.1M 12.37% | 662.59M 10.23% | 734.91M 10.91% | 835.4M 13.67% | 930.96M 11.44% | 1.038B 11.50% | 1.157B 11.46% | 1.197B 3.46% | |
| Operating Margin | 17.86% | 21.19% | 21.14% | 21.01% | 21.55% | 21.86% | 21.76% | 22.09% | 22.36% | 22.64% | 23.31% | |
| EPS YoY % growth | 8.88 21.31% | 12.63 42.23% | 15.30 21.14% | 16.81 9.87% | 18.69 11.17% | 20.47 9.53% | 22.57 10.26% | 24.96 10.62% | 27.62 10.62% | 30.54 10.58% | 30.61 0.23% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 3.98 8.37% | 4.16 34.07% | 4.42 14.43% | 4.56 -2.44% | 4.25 6.95% | 4.64 11.57% | 5.02 13.75% | 5.17 13.56% |
| Revenue Q2Q % growth | 712.08M 27.48% | 715.7M 18.63% | 726.74M 10.13% | 743.37M 4.93% | 736.6M 3.44% | 762.02M 6.47% | 794.81M 9.37% | 817.85M 10.02% |
| EBITDA Q2Q % growth | 142.96M 18.69% | 152.85M 8.96% | 160.53M -1.39% | 165.76M -8.62% | 152.67M 6.79% | 165.87M 8.52% | 178.92M 11.46% | 183.61M 10.77% |
| EBIT Q2Q % growth | 136.28M 20.05% | 145.27M 14.99% | 153.37M 8.15% | 160.52M 4.73% | 142.79M 4.78% | 158.58M 9.16% | 173.15M 12.90% | 177.45M 10.55% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.19%
EPS Next 5 Year
10.29%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
9.50%
Revenue Next 5 Year
10.47%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
12.32%
EBIT Next 5 Year
12.46%
MEDPACE HOLDINGS INC / MEDP Forecast FAQ
Can you provide the average price target for MEDPACE HOLDINGS INC stock?
18 analysts have analysed MEDP and the average price target is 497.46 USD. This implies a price increase of 5.71% is expected in the next year compared to the current price of 470.59.
Can you provide the upcoming earnings date for MEDPACE HOLDINGS INC?
MEDPACE HOLDINGS INC (MEDP) will report earnings on 2026-04-20, after the market close.
What are the consensus estimates for MEDP stock next earnings?
The consensus EPS estimate for the next earnings of MEDPACE HOLDINGS INC (MEDP) is 3.98 USD and the consensus revenue estimate is 712.08M USD.
Can you provide the analyst count for MEDPACE HOLDINGS INC stock?
The number of analysts covering MEDPACE HOLDINGS INC (MEDP) is 18.